Protara Therapeutics, Inc. (TARA) Stock Profile — Insider Trades & Financials

Net Income-$17.3M

EPS$-0.96

Market Cap$282.3M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Jesse Shefferman

CEO & Executive Director

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The companyâs lead program is TARA-002, an investigational cell therapy, which is in phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.

Employees: 46
Headquarters: New York, New York, United States
Website: www.protaratx.com

⚡

Core Efficiency

ROE?

-8.81%

ROA?

-8.26%

D/E Ratio?

0.07

📊

Profitability Ratios

Current Ratio?

14.58

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Aug 12, 2026 (in 125 days)

Annual Report (10-K) — Based on filing pattern

Aug 12, 2026

Predicted10-K

Mar 10, 2026

10-KQ4 20255d after period end

Mar 10, 2026

10-KFY 202569d after period end

Nov 10, 2025

10-QQ3 20254d after period end

Aug 11, 2025

10-QQ2 20255d after period end

May 8, 2025

10-QQ1 20257d after period end

Mar 5, 2025

10-KQ4 20245d after period end

Mar 5, 2025

10-KFY 202564d after period end

Nov 12, 2024

10-QQ3 20245d after period end

Loading company sections...

Protara Therapeutics, Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness